Pharmacological management of atrial fibrillation following cardiac surgery

被引:18
作者
Hilleman D.E. [1 ,2 ]
Hunter C.B. [1 ]
Mohiuddin S.M. [1 ]
Maciejewski S. [1 ]
机构
[1] Creighton University Cardiac Center, Omaha, NE
[2] Creighton University Cardiac Center, Omaha, NE 68131
关键词
Atrial Fibrillation; Digoxin; Coronary Artery Bypass Graft; Amiodarone; Diltiazem;
D O I
10.2165/00129784-200505060-00003
中图分类号
学科分类号
摘要
Atrial fibrillation (AF) is the most common complication following coronary artery bypass graft surgery (CABG). Post-CABG AF occurs most commonly on the second postoperative day and declines in incidence thereafter. A number of risk factors have been found to be associated with a higher frequency of post-CABG AF. These risk factors include advanced age, a prior history of AF, hypertension, and heart failure. Postoperative complications - including low cardiac output, use of an intra-aortic balloon pump, pneumonia, and prolonged mechanical ventilation - are also associated with higher rates of post-CABG AF. Post-CABG AF increases the risk of stroke, and the length and cost of hospitalization. Prophylactic administration of conventional β-adrenoceptor antagonists (β-blockers) or sotalol produces a consistent and significant reduction in the incidence of post-CABG AF; however, results with prophylactic amiodarone or magnesium are less consistent. Termination of post-CABG AF, once it occurs, can be accomplished with a number of antiarrhythmic agents. Ibutilide has been the most widely studied agent for this indication. Sotalol is not indicated for cardioversion of AF and has not been studied in the post-CABG setting. Electrical cardioversion and biatrial pacing have also been used to terminate post-CABG AF. Ventricular rate is best controlled with β-blockers and calcium channel antagonists. Esmolol has a rapid onset of action and is easily titrated to effect. Digoxin can control the ventricular rate, but has a slow onset of action. There are limited data available to guide decisions regarding the optimal management of post-CABG AF. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码:361 / 369
页数:8
相关论文
共 73 条
[21]  
Stamou S.C., Hill P.C., Dangas G., Et al., Stroke after coronary artery bypass: Incidence, predictors, and clinical outcome, Stroke, 32, pp. 1508-1513, (2001)
[22]  
Lahtinen J., Biancari F., Salmela E., Et al., Postoperative atrial fibrillation is a major cause of stroke after on-pump coronary artery bypass surgery, Ann Thorac Surg, 77, pp. 1241-1244, (2004)
[23]  
Stamou S.C., Jablonski K.A., Pfister A.J., Et al., Stoke after conventional versus minimally invasive coronary artery bypass, Ann Thorac Surg, 74, pp. 394-399, (2002)
[24]  
Reed G.L., Singer D.E., Picard E.H., Et al., Stroke following coronary-artery bypass surgery: A case-control estimate of the risk from carotid bruits, N Engl J Med, 319, pp. 246-250, (1988)
[25]  
Kapetanakis E.I., Stamou S.C., Dullum M.K., Et al., The impact of aortic manipulation on neurologic outcomes after coronary artery bypass surgery: A risk adjusted study, Ann Thorac Surg, 78, pp. 1564-1571, (2005)
[26]  
Davison R., Hertz R., Kaplan K., Et al., Prophylaxis of supraventricular tachyarrhythmias after coronary artery bypass surgery with oral verapamil: A randomized, double-blinded trial, Ann Thorac Surg, 39, pp. 336-339, (1985)
[27]  
Hravnak M., Hoffman L.A., Saul M.I., Et al., Resource utilization related to atrial fibrillation after coronary artery bypass grafting, Am J Crit Care, 11, 3, pp. 228-238, (2002)
[28]  
Crystal E., Connolly S.J., Sleik K., Et al., Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: A meta-analysis, Circulation, 106, pp. 75-80, (2002)
[29]  
Hohnloser S.H., Meinertz J., Dammbacher T., Et al., Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: Results of a prospective, placebo-controlled study, Am Heart J, 121, pp. 89-95, (1991)
[30]  
Butler J., Harriss D.R., Sinclair M., Et al., Amiodarone prophylaxis for tachycardias after coronary artery surgery: A randomized, double-blind, placebo controlled trial, Br Heart J, 70, pp. 56-60, (1993)